Scholar Rock (NASDAQ:SRRK) COO Keith Woods Sells 10,220 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) COO Keith Woods sold 10,220 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the completion of the transaction, the chief operating officer directly owned 620,055 shares of the company’s stock, valued at approximately $30,736,126.35. This trade represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $47.80 on Tuesday. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $51.63. The firm has a 50 day simple moving average of $46.16 and a 200-day simple moving average of $42.12. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.95 and a quick ratio of 6.95. The firm has a market cap of $5.49 billion, a PE ratio of -13.94 and a beta of 0.68.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter last year, the company posted ($0.64) EPS. On average, equities analysts expect that Scholar Rock Holding Corporation will post -3.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on SRRK shares. Citigroup lifted their price target on shares of Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Piper Sandler lifted their target price on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. upped their price target on Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 16th. Raymond James Financial reiterated a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $55.40.

Institutional Investors Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently modified their holdings of SRRK. Siren L.L.C. grew its stake in shares of Scholar Rock by 17.0% in the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after buying an additional 1,575,008 shares in the last quarter. Wellington Management Group LLP lifted its position in Scholar Rock by 26.7% during the 4th quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock worth $253,703,000 after acquiring an additional 1,213,541 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Scholar Rock by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock worth $228,860,000 after acquiring an additional 280,538 shares during the period. State Street Corp grew its position in Scholar Rock by 7.2% in the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock valued at $177,717,000 after acquiring an additional 271,331 shares in the last quarter. Finally, Orbis Allan Gray Ltd grew its position in Scholar Rock by 1,034.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after acquiring an additional 3,126,677 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).